Essa Pharma Stock Total Debt
| EPIX Stock | USD 0.19 0 2.16% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess ESSA Pharma's long-term financial health and intrinsic value.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. ESSA Pharma Company Total Debt Analysis
ESSA Pharma's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current ESSA Pharma Total Debt | 329.26 K |
Most of ESSA Pharma's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ESSA Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
ESSA Total Debt Historical Pattern
Today, most investors in ESSA Pharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various ESSA Pharma's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of ESSA Pharma total debt as a starting point in their analysis.
ESSA Pharma Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Based on the latest financial disclosure, ESSA Pharma has a Total Debt of 329.26 K. This is 99.99% lower than that of the Biotechnology sector and 99.9% lower than that of the Health Care industry. The total debt for all United States stocks is 99.99% higher than that of the company.
ESSA Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ESSA Pharma's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ESSA Pharma could also be used in its relative valuation, which is a method of valuing ESSA Pharma by comparing valuation metrics of similar companies.ESSA Pharma is currently under evaluation in total debt category among its peers.
ESSA Pharma Institutional Holders
Institutional Holdings refers to the ownership stake in ESSA Pharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of ESSA Pharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing ESSA Pharma's value.| Shares | Bnp Paribas Arbitrage, Sa | 2025-06-30 | 271.2 K | Two Sigma Advisers, Llc | 2025-06-30 | 260.8 K | Two Sigma Investments Llc | 2025-06-30 | 222.3 K | Lmr Partners Llp | 2025-06-30 | 200 K | Jpmorgan Chase & Co | 2025-06-30 | 189.1 K | Group One Trading, Lp | 2025-06-30 | 83.8 K | Magnus Financial Group Llc | 2025-06-30 | 55.2 K | Citadel Advisors Llc | 2025-06-30 | 54 K | Adar1 Capital Management Llc | 2025-06-30 | 50 K | Bvf Inc | 2025-06-30 | 8.7 M | Tang Capital Management Llc | 2025-06-30 | 4.3 M |
ESSA Fundamentals
| Return On Equity | -0.21 | ||||
| Return On Asset | -0.15 | ||||
| Current Valuation | (100.11 M) | ||||
| Shares Outstanding | 47.31 M | ||||
| Shares Owned By Insiders | 5.64 % | ||||
| Shares Owned By Institutions | 73.70 % | ||||
| Number Of Shares Shorted | 1.35 M | ||||
| Price To Earning | (1.12) X | ||||
| Price To Book | 0.09 X | ||||
| EBITDA | (28.45 M) | ||||
| Net Income | (28.54 M) | ||||
| Cash And Equivalents | 174.6 M | ||||
| Cash Per Share | 3.96 X | ||||
| Total Debt | 329.26 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 43.43 X | ||||
| Book Value Per Share | 2.45 X | ||||
| Cash Flow From Operations | (22.72 M) | ||||
| Short Ratio | 0.08 X | ||||
| Earnings Per Share | (0.57) X | ||||
| Target Price | 1.74 | ||||
| Number Of Employees | 35 | ||||
| Beta | 1.55 | ||||
| Market Capitalization | 9.51 M | ||||
| Total Asset | 128.11 M | ||||
| Retained Earnings | (208 M) | ||||
| Working Capital | 124.26 M | ||||
| Current Asset | 10.02 M | ||||
| Current Liabilities | 3.63 M | ||||
| Annual Yield | 0.88 % | ||||
| Net Asset | 128.11 M |
About ESSA Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ESSA Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ESSA Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ESSA Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for ESSA Stock Analysis
When running ESSA Pharma's price analysis, check to measure ESSA Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ESSA Pharma is operating at the current time. Most of ESSA Pharma's value examination focuses on studying past and present price action to predict the probability of ESSA Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ESSA Pharma's price. Additionally, you may evaluate how the addition of ESSA Pharma to your portfolios can decrease your overall portfolio volatility.